


Real world efficacy of dupilumab in switchers versus biological naive CRSwNP patients

Study population

Severe CRSwNP treated with dupilumab
n = 55




Group 1: Switchers
n = 25




Group 2: Biological naive
n = 30




Methods



Results



Significant reduction upper and lower airway symptoms in both groups



Biological naive patients achieve higher TRE and disease control at 6 months